Reporte zur Charge FN9222

Symptomtext

COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 58-year-old male patient received BNT162b2 (BNT162B2), on 24Mar2021 as dose 1, single (Lot number: EP7533), on 15Apr2021 as dose 2, single (Lot number: ER8731), on 02Dec2021 as dose 3 (booster), single (Lot number: Fj8762) and on 12May2022 as dose 4 (booster), single (Lot number: FN9222) at the age of 57 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Parkinson" (unspecified if ongoing), notes: other medical history: Parkinson. Concomitant medication(s) included: SINEMET, start date: 29Sep2019; EFFEXOR, start date: 31May2021; ZYRTEC [CETIRIZINE HYDROCHLORIDE]; MELATONIN, start date: 31May2021. Past drug history included: Sensitive to codeine, reaction(s): "Allergy", notes: known allergies: Sensitive to codeine. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical course: Report about covid treatment reported as Yes. if vaccine received reported Yes. other medication in 2weeks reported as Yes. Anti viral details product: COVID 19 Treatment, brand: Paxlovid, treatment start date: 14Jun2022, treatment stop date: 18Jun2022, indication: Treatment of COVID-19. Adverse event reported as Rebound case of Covid 6 days after completion of course of Paxlovid.